米非司酮治疗子宫肌瘤的疗效相关因子研究

目的研究米非司酮治疗子宫肌瘤疗效相关的因子。方法选取绝经前子宫肌瘤患者66例,分为两组,一组为米非司酮治疗后再行手术组,另一组为直接手术组。第一组病人治疗前后分别用B超测量肌瘤的三维经线,肌瘤体积缩小≥20%为治疗有效。采用SP法进行免疫组化染色,分别比较治疗组和未治疗组、治疗有效组和治疗无效组中IGF-1、TGF-β、肥大细胞的表达差异。结果 (1)在米非司酮治疗组和未用药物组中,IGF-1的表达分别为2.18±2.49和3.31±1.96,两组比较有显著性差异(P<0.05),而TGF-β和肥大细胞的表达在两组间没有差异(P>0.05)。(2)在米非司酮治疗有效组和无效组中,IGF-1的表达分别为3.30±2.68和0.57±0.76,两组比较有显著性差异(P<0.05),而TGF-β和肥大细胞在两组中的表达无差异(P>0.05)。结论米非司酮下调了子宫肌瘤中IGF-1的表达,IGF-1的表达与米非司酮治疗子宫肌瘤的疗效相关。

Study on Related Factor of Mifepristone Treatment for Uterine Leiomyoma

Objective To study the related factor of mifepristone treatment for uterine leiomyoma.Methods Sixty-six premenopausal women with uterine leiomyoma received mifepristone before operation or operation directly.Women who received mifepristone before operation divided into effective group and ineffective group.Uterine volume was measured at the start and end of using mifepristone by sonography.Uterine volume shrinkage more than or equal to 20% was defined effectively.The expression of IGF-1,TGF-β and mast cells between groups were compared using SP immunohistochenmical staining method.Results(1) The expression of IGF-1 was 2.18±2.49 in the mifepristone treatment group,which has significant difference to that in untreated group 3.31±1.96(P<0.05).But the expression of TGF-β and mast cells had no significant difference between them.(2) The expression of IGF-1 was 3.30±2.68 in the effective group,which had significant difference to that in the ineffective group(0.57±0.76)(P<0.05),while the expression of TGF-β and mast cells had no significant difference between them.Conclusion Mifepristone down-regulates the expression of IGF-1 in uterine leiomyoma.The expression of IGF-1 is an important related factor of mifepristone treatment for uterine leiomyoma.